ArticleCureus2026
Combined High Dose-Rate Interstitial Brachytherapy and Stereotactic Body Radiotherapy in Unresectable Primary Vaginal Melanoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary vaginal melanoma is a rare and aggressive malignancy with limited prospective data to guide optimal management, particularly in unresectable disease. This report describes a 40-year-old woman with unresectable, locally progressive primary vaginal melanoma refractory to first-line combination immune checkpoint inhibition. She was treated with a dose-escalated, multimodality radiotherapy approach incorporating high-dose-rate interstitial brachytherapy to the primary tumor and stereotactic body radiotherapy with simultaneous integrated boost to nodal disease. Treatment was well tolerated and resulted in a complete metabolic and radiographic response at one year. This case highlights the role of integrated, hypofractionated radiotherapy strategies in achieving durable locoregional control in patients with progressive disease despite systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.